Correction: Classification, Synthetic, and Characterization Approaches to Nanoparticles, and Their Applications in Various Fields of Nanotechnology: A Review (Catalysts, (2022), 12, 11, (1386), 10.3390/catal12111386)

In the original publication [1], there were mistakes in the references and citation of references. Section 3.1.1., Paragraph 4: “Hydrogen, for instance, can be trapped and stored in the porosity of a nanoporous carbon material [69–72].” We apologize for the four incorrect citations of the references [69–72] and for any inconvenience this may have caused. The following references are more relevant and appropriately discuss hydrogen storage in porous carbon-based materials. We replaced the references [69,70] with the following new references: 69. Ting, V.P.; Ramirez-Cuesta, A.J.; Bimbo, N.; Sharpe, J.E.; Noguera-Diaz, A.; Presser, V.; Rudic, S.; Mays, T.J. Direct Evidence for Solid-like Hydrogen in a Nanoporous Carbon Hydrogen Storage Material at Supercritical Temperatures. ACS Nano 2015, 9, 8249–8254. https://doi.org/10.1021/acsnano.5b02623. 70. Züttel, A.; Sudan, P.; Mauron, P.; Wenger, P. Model for the Hydrogen Adsorption on Carbon Nanostructures. Appl. Phys. A 2004, 78, 941–946. https://doi.org/10.1007/s00339-003-2412-1. The references [71,72] have been deleted from the paper. Section 6.6., Paragraph 1: “In 1995, the United States Food and Drug Administration granted clinical permission for the use of the first nanoparticle-based drug, liposomal doxorubicin (Doxil^®), for the treatment of cancer. This event marked the introduction of nanomedicines to the market [173].” We again apologize for the incorrect citation of reference [173] and have removed reference [173] from the paper. Since two references [71,72] have been deleted, the previous reference [172] has been renumbered [170]. Two new references were added after it and numbers as [171,172]: 171. Barenholz, Y. Doxil^®—The First FDA-Approved Nano-Drug: Lessons Learned. J. Control. Release 2012, 160, 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020. 172. U.S. Food and Drug Administration. DOXIL^® (Doxorubicin HCl Liposome Injection) Highlights of Prescribing Information. FDA Label Information 2022. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050718Orig1s060lbl.pdf (accessed on 6 March 2026). The corrected Section 6.6., Paragraph 1: “In 1995, the United States Food and Drug Administration granted clinical permission for the use of the first nanoparticle-based drug, liposomal doxorubicin (Doxil^®), for the treatment of cancer. This event marked the introduction of nanomedicines to the market [171,172].” With this correction, the order of some references has been adjusted accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.